In Brief: Cytogen's ProstaScint
This article was originally published in The Gray Sheet
Cytogen's ProstaScint: C.R. Bard will copromote the prostate cancer diagnostic capromab pendetide under a 10-year agreement announced Aug. 1. The deal calls for Bard to market the monoclonal antibody imaging agent to office and hospital-based urologists. Cytogen will be responsible for the completion of clinical trials, regulatory activities related to the PLA, manufacturing, distribution and marketing to the medical imaging community. Both companies will market the monoclonal antibody-based product to managed care organizations. Cytogen has said it plans initially to restrict availability of the imaging agent to certified sites. On July 22, FDA's Medical Imaging Drugs Advisory Committee unanimously recommended ProstaScint for detection of metastatic prostate cancer in high-risk patients to aid surgical staging and to detect recurrence of prostatic carcinoma...
You may also be interested in...
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.
Sabinsa provided FDA and FTC with documentation of “an ingredient falsely marketed and sold as vitamin C derived from amla fruit (Emblica officinalis), which two independent labs have confirmed is actually derived from corn, sugarcane or other plants.”